Under the terms of the agreement, CMC Biologics, which is owned by Asahi Glass Compnay, will employ its proprietary CHEF1 expression platform and multi-column continuous chromatography (MCC) technology to develop and manufacture two of Trellis’ mAbs.
Trellis CEO Stefan Ryser said the mAb-based therapies aim to treat respiratory syncytial virus (RSV) infections and bacterial infections respectively.
Ryser said the RSV infection-focused therapy “promises to provide superior post-infection treatment over the currently marketed mAb (palivizumab) by uniquely combining antiviral and anti-inflammatory activity.”
The other candidate – TRL1068 – is designed to treat bacterial infections that are drug-resistant due to the formation of bacterial biofilms.
“By disrupting the biofilm, TRL1068 acts to resensitise bacteria to conventional antibiotics, with broad-spectrum activity spanning from medically important gram-positive to gram-negative bacterial species, including MRSA [methicillin resistant staphylococcus aureus antibody] and Acinetobacter baumanni,” Ryser explained.
According to Ryser, the use of CMC Biologics’ technologies will reduce costs in the downstream process.
“Through CMC Biologics’ use of MCC technology, where a reduced quantity of costly chromatography resins is required in the downstream process, CMC Biologics is able to provide Trellis a significant reduction in our development and manufacturing costs.”